QIAGEN N.V. (QGEN) stock
QGENNYSEBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$49.56−0.19 (-0.38%)
Close on Nov 18, 2026Market cap $10.75BP/E 25.5Yield 0.50%
Qiagen pe ratio
The price-to-earnings ratio is the share price divided by diluted earnings per share over the trailing twelve months.
Qiagen's pe ratio was 25.9× on Nov 11, 2026, against 135.8× a year earlier. Over the last 5 years it ranged from 17.8× to 145.1×, with a median of 26.0×.
PE Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 25.9× | −102.0 |
| 2025 | Dec 31, 2025 | 127.9× | +97.9 |
| 2024 | Dec 31, 2024 | 30.1× | +5.2 |
| 2023 | Dec 29, 2023 | 24.8× | +1.1 |
| 2022 | Dec 30, 2022 | 23.8× | −14.5 |
| 2021 | Dec 31, 2021 | 38.2× | −7.8 |
| 2020 | Feb 28, 2020 | 46.1× | +2.7 |
| 2019 | Dec 31, 2019 | 43.4× | −169.9 |
| 2018 | Dec 31, 2018 | 213.3× | +117.5 |
| 2017 | Dec 29, 2017 | 95.8× | +42.1 |
| 2016 | Dec 30, 2016 | 53.6× | −7.0 |
| 2015 | Dec 31, 2015 | 60.6× | −24.5 |
| 2014 | Dec 31, 2014 | 85.1× | +38.7 |
| 2013 | Dec 31, 2013 | 46.4× | −1.4 |
| 2012 | Dec 31, 2012 | 47.8× | +23.5 |
| 2011 | Dec 30, 2011 | 24.2× | −7.9 |
| 2010 | Dec 31, 2010 | 32.2× | −21.3 |
| 2009 | Dec 31, 2009 | 53.4× | – |
See a number that looks wrong?